{"id":46089,"date":"2017-03-21T03:35:21","date_gmt":"2017-03-21T08:35:21","guid":{"rendered":"https:\/\/3768346-fork.findlaw4.flsitebuilder.com\/?p=46089"},"modified":"2017-03-21T03:35:21","modified_gmt":"2017-03-21T08:35:21","slug":"the-seiden-group-announces-u-s-shareholders-formation-of-a-group-to-recover-investor-funds-through-a-possible-receivership-over-china-based-bio-pharm-asia-inc-tickerbfar","status":"publish","type":"post","link":"https:\/\/seidenlaw.com\/ru\/blog\/2017\/03\/the-seiden-group-announces-u-s-shareholders-formation-of-a-group-to-recover-investor-funds-through-a-possible-receivership-over-china-based-bio-pharm-asia-inc-tickerbfar\/","title":{"rendered":"\u041a\u043e\u043c\u043f\u0430\u043d\u0438\u044f Seiden Law \u043e\u0431\u044a\u044f\u0432\u0438\u043b\u0430 \u043e \u0441\u043e\u0437\u0434\u0430\u043d\u0438\u0438 \u0433\u0440\u0443\u043f\u043f\u044b \u0430\u043a\u0446\u0438\u043e\u043d\u0435\u0440\u043e\u0432 \u0432 \u0421\u0428\u0410 \u0441 \u0446\u0435\u043b\u044c\u044e \u0432\u043e\u0437\u0432\u0440\u0430\u0449\u0435\u043d\u0438\u044f \u0441\u0440\u0435\u0434\u0441\u0442\u0432 \u0438\u043d\u0432\u0435\u0441\u0442\u043e\u0440\u043e\u0432 \u0447\u0435\u0440\u0435\u0437 \u0432\u043e\u0437\u043c\u043e\u0436\u043d\u044b\u0439 \u043f\u0440\u043e\u0446\u0435\u0441\u0441 \u0440\u0435\u043e\u0440\u0433\u0430\u043d\u0438\u0437\u0430\u0446\u0438\u0438 \u043a\u043e\u043c\u043f\u0430\u043d\u0438\u0438 China-Based Bio-pharm Asia, Inc. (ticker:BFAR)."},"content":{"rendered":"<p>BioPharm Asia, Inc., (ticker:\u201dBFAR\u201d), is a Nevada corporation involved in the sale of medical products to drug stores, hospitals, neighborhood clinics, and other medicine retail outlets in the People\u2019s Republic of China. BFAR was de-listed from the NASDAQ in June 2013 after it stopped reporting to the Securities &amp; Exchange Commission (\u201cSEC\u201d).<\/p>\n<p>Certain shareholders have spoken with Robert W. Seiden, Esq. in New York to represent a group of shareholders to enforce the rights of the U.S. shareholders for acts detrimental to the investors including failure to report to the SEC in order to get a possible return of capital to the investors. .\u00a0.<\/p>\n<p><a href=\"https:\/\/www.marketwatch.com\/press-release\/the-seiden-group-announces-us-shareholders-formation-of-a-group-to-recover-investor-funds-through-a-possible-receivership-over-china-based-biopharm-asia-inc-ticker-bfar-2017-03-21\" target=\"_blank\" rel=\"noopener\">\u0427\u0438\u0442\u0430\u0442\u044c \u0434\u0430\u043b\u0435\u0435<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>\u041a\u043e\u043c\u043f\u0430\u043d\u0438\u044f BioPharm Asia, Inc. (ticker: \u201dBFAR\u201d), \u044f\u0432\u043b\u044f\u0435\u0442\u0441\u044f \u043a\u043e\u0440\u043f\u043e\u0440\u0430\u0446\u0438\u0435\u0439 \u0448\u0442\u0430\u0442\u0430 \u041d\u0435\u0432\u0430\u0434\u0430, \u0437\u0430\u043d\u0438\u043c\u0430\u044e\u0449\u0435\u0439\u0441\u044f \u043f\u0440\u043e\u0434\u0430\u0436\u0435\u0439 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0445 \u0442\u043e\u0432\u0430\u0440\u043e\u0432 \u0430\u043f\u0442\u0435\u043a\u0430\u043c, \u0431\u043e\u043b\u044c\u043d\u0438\u0446\u0430\u043c, \u0440\u0430\u0439\u043e\u043d\u043d\u044b\u043c \u043a\u043b\u0438\u043d\u0438\u043a\u0430\u043c \u0438 \u0434\u0440\u0443\u0433\u0438\u043c \u043e\u0440\u0433\u0430\u043d\u0438\u0437\u0430\u0446\u0438\u044f\u043c, \u0437\u0430\u043d\u0438\u043c\u0430\u044e\u0449\u0438\u043c\u0441\u044f \u0440\u043e\u0437\u043d\u0438\u0447\u043d\u043e\u0439 \u043f\u0440\u043e\u0434\u0430\u0436\u0435\u0439 \u043b\u0435\u043a\u0430\u0440\u0441\u0442\u0432...<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-46089","post","type-post","status-publish","format-standard","hentry","category-firm-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/posts\/46089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/comments?post=46089"}],"version-history":[{"count":0,"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/posts\/46089\/revisions"}],"wp:attachment":[{"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/media?parent=46089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/categories?post=46089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seidenlaw.com\/ru\/wp-json\/wp\/v2\/tags?post=46089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}